Glial Restricted Progenitor Cell Sorting for Remyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for restoring myelin in demyelinated neurons are inadequate due to complex intercellular interactions and signals required for regeneration, leading to insufficient endogenous remyelination in patients with demyelinating diseases or trauma, despite some animal model benefits from cellular therapy.
Innovation Solution
Manufacturing mammalian glial restricted progenitor (GRP) cells with decreased unintended cellular phenotypes and standard deviations, using a method involving A2B5 antibody sorting and extended in vitro culture on substrates, and characterizing them with a specific antibody panel, followed by differentiation into astrocytes and oligodendrocytes for remyelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cellular therapy is used to restore myelin in demyelinated neurons, then remyelination and partial return of function can be achieved, but the complex intercellular interactions and signals required make the process difficult to control and reproduce
Solution Approach 1:
The patent extracts and isolates specific progenitor cell populations (A2B5+ GRP cells) from complex neural tissue, separating the remyelination function from the complex intercellular environment. By culturing these cells in defined media and sorting them by surface markers, the invention creates a simplified, controllable cell product that can be transplanted without requiring complex in vivo interactions during production.
Solution Approach 2:
The patent segments the neural progenitor population into distinct subsets based on surface marker expression (A2B5+, GFAP+, PSA-NCAM-). This segmentation allows selection of specific cell types with desired properties (glial differentiation potential without neuronal differentiation), enabling controlled remyelination without the complexity of heterogeneous cell populations.
2Adaptability or versatility
If neural stem cells are used for therapy, then they can differentiate into multiple cell types including neurons, but this may lead to unintended cellular phenotypes and teratoma formation
Solution Approach 1:
The patent extracts A2B5+ GRP cells from heterogeneous neural stem cell populations and removes unwanted cell types through antibody sorting. This extraction process isolates cells with specific differentiation potential (astrocytes and oligodendrocytes) while eliminating cells that could form tumors or differentiate into neurons, creating a safer therapeutic product.
Solution Approach 2:
The patent applies local quality by giving different cell populations distinct fates through selective isolation. A2B5+ GRP cells are specifically selected to become glial cells (astrocytes and oligodendrocytes), while other populations are excluded. This localized differentiation instruction ensures cells only become appropriate cell types for the intended therapeutic effect.
3Quantity of substance
If GRP cells are cultured for extended periods in vitro, then cell quantity increases for therapeutic use, but cell phenotype may drift and standard deviation increases
Solution Approach 1:
The patent implements feedback control by using surface marker expression (A2B5, GFAP, PSA-NCAM) as indicators of cell state. During culture, cells are monitored for marker expression changes, and sorting is performed based on these markers to maintain phenotype consistency. This feedback mechanism ensures that even after extended culture, the cell population remains homogeneous and therapeutically appropriate.
Solution Approach 2:
The patent uses parameter changes in surface marker expression levels to identify and sort cells at optimal differentiation stages. By monitoring and selecting cells based on specific marker thresholds (A2B5+, GFAP+, PSA-NCAM-), the process maintains phenotype consistency while allowing cells to progress through culture to achieve sufficient numbers for therapy.
4Measurement precision
If multiple antibody markers are used to characterize GRP cells, then cell identification accuracy improves, but the characterization process becomes more complex
Solution Approach 1:
The patent segments cell identification into a hierarchical process using three key markers at different stages: A2B5 for initial GRP identification, GFAP for astrocytic differentiation confirmation, and PSA-NCAM for neuronal differentiation exclusion. This segmented approach using minimal essential markers achieves accurate identification without requiring comprehensive panels of all possible neural markers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces GRP cells that effectively remyelinate neurons, reduce glial scar formation, and treat neurodegenerative diseases by differentiating into regionally appropriate cell types, demonstrating improved cell viability and therapeutic efficacy in animal models of demyelination and neurodegenerative disorders.
Implementation Method 1
Glial restricted progenitor cells (GRPs) are defined by their reactivity with antibody A2B5, which recognizes a subset of c-series gangliosides
Implementation Method 2
Other antigenic characteristics of GRPs include moderate expression of the astrocytic marker glial fibrillary acidic protein (GFAP) and low expression of the neuronal markers E-CAM (polysialated N-CAM, or PSA-NCAM) and β-III tubulin (TuJ1)
Data Source
AI summary
Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.